|
|
晚期胃癌分子靶向与免疫治疗相关性研究
|
Abstract:
胃癌(gastric cancer, GC)是一种广泛存在于全球的恶性肿瘤，每年约有一千万到两千万的GC患者，其中以老年人居多，在我国，胃癌的发病率和死亡率均排在第二位。由于早期胃癌往往没有明显的临床表现，且患者缺乏相关的医学知识，对此并不了解，往往被忽略或者处理不当，大部分病人在发现时已是中、晚期，错过了最好的手术治疗时间。因此，GC已成为一个重要的临床问题，近年来，国内外的许多学者都致力于寻找新的诊断与治疗手段。对于中晚期胃癌患者，尽管化学疗法能提高病人的生命和生存质量，但是总体化疗效果不佳，不能保证长期生存。近年来，随着分子生物学技术的飞速发展，很多学者开发出了新的肿瘤靶向、免疫治疗药物，现对近几年来胃癌分子靶向与免疫治疗的现状和进展做一综述。
Gastric cancer (GC) is a kind of malignant tumor that exists widely worldwide. There are about 10 million to 20 million GC patients each year. Most of them are the elderly. In my country, the inci-dence and mortality of gastric cancer are ranked second. Because early gastric cancer often has no obvious clinical manifestations, and patients lack related medical knowledge, they do not under-stand this, and are often ignored or mishandled. Most patients were already in the middle and late stage when they discovered, and missed the best surgical treatment time. Therefore, GC has become an important clinical issue. In recent years, many scholars at home and abroad have been commit-ted to finding new diagnosis and treatment methods. For patients with gastric cancer in the middle and advanced periods, although chemotherapy can improve the quality of life and survival of pa-tients, the overall chemotherapy effect is not good and cannot guarantee long-term survival. In re-cent years, with the rapid development of molecular biology technology, many scholars have de-veloped new tumor-targeted and immunotherapy drugs. This article reviews the current status and progress of molecular targeted therapy and immunotherapy for gastric cancer in recent years.
| [1] | 孙晓琨. 近四十年来我国消化系统癌症的发病状况及其危险因素研究[D]: [硕士学位论文]. 遵义: 遵义医科大学, 2021. https://doi.org/10.27680/d.cnki.gzyyc.2021.000415 |
| [2] | 王静雷, 杨一兵, 耿云霞, 石文惠, 高欣, 马吉祥. 1990-2017年中国胃癌发病、患病及死亡状况趋势分析[J]. 中国慢性病预防与控制, 2020, 28(5): 321-325. https://doi.org/10.16386/j.cjpccd.issn.1004-6194.2020.05.001 |
| [3] | 包润发, 吕文杰, 李茂岚, 等. GEMOX方案联合靶向药物治疗晚期胆囊癌的临床疗效[J]. 中华消化外科杂志, 2019, 18(2): 140-145. |
| [4] | 王娜, 郭军, 孙雅薇, 等. 雷替曲塞注射剂联合奥沙利铂注射剂治疗晚期胃癌的临床研究[J]. 中国临床药理学杂志, 2017, 33(19): 1886-1888. |
| [5] | Cho, M., Gong, J., Frankel, P., et al. (2017) A Phase I Clinical Trial of Binimetinibin Combination with FOLFOX in Patients with Advanced Metastatic Colorectal Cancer Who Failed Prior Standard Therapy. Oncotarget, 8, 79750-79760.
https://doi.org/10.18632/oncotarget.19336 |
| [6] | Mishra, R., Patel, H., Alanazi, S., Yuan, L. and Garrett, J.T. (2018) HER3 Signaling and Targeted Therapy in Cancer. Oncology Reviews, 12, 45-62. https://doi.org/10.4081/oncol.2018.355 |
| [7] | Raimundez, E., Keller, S., Zwingenberger, G., et al. (2020) Mod-el-Based Analysis of Response and Resistance Factors of Cetuximab Treatment in Gastric Cancer Cell Lines. PLOS Computational Biology, 16, e1007147.
https://doi.org/10.1371/journal.pcbi.1007147 |
| [8] | 刘卓. 西妥昔单抗联合铂类药物灌注治疗胃癌所致恶性腹水患者的临床效果观察[J]. 医学理论与实践, 2022, 35(7): 1146-1148. https://doi.org/10.19381/j.issn.1001-7585.2022.07.027 |
| [9] | 王鑫璐, 景啸澜, 曲晓宇, 李艳娇. 73例西妥昔单抗不良反应文献分析[J]. 中国药物应用与监测, 2021, 18(4): 252-255. |
| [10] | 张培良, 张焕珍, 张丹丹. 3DRT辅助卡培他滨与奥沙利铂化疗方案对进展期胃癌术后生存研究[J]. 中华放射肿瘤学杂志, 2018, 27(7): 661-664. |
| [11] | Kimura, Y., Fujii, M., Masuishi, T., et al. (2017) Multicenter Phase II Study of Trastuzumab Plus S-1 Alone in Elderly Patients with HER2-Positive Advanced Gastric Cancer (JACCRO GC-06). Gastric Cancer, 21, 421-427.
https://doi.org/10.1007/s10120-017-0784-8 |
| [12] | 张艳. 胃癌患者抗肿瘤治疗中奥沙利铂联合曲妥珠单抗作用机制研究[J]. 山西医药杂志, 2020, 49(18): 2511-2513. |
| [13] | Wang, Y.K., Wang, S.N., Li, Y.Y., et al. (2017) Meth-ods and Significance of the Combined Detection of HER2 Gene Amplification and Chemosensitivity in Gastric Cancer. Cancer Biomarkers, 21, 439-447. |
| [14] | 李红, 史长山. 曲妥珠单抗辅助治疗HER2阳性晚期胃癌的安全性及对患者血清肿瘤标志物的影响研究[J]. 长春中医药大学学报, 2022, 38(1): 88-92. https://doi.org/10.13463/j.cnki.cczyy.2022.01.021 |
| [15] | Lemmon, M.A. and Schlessinger, J. (2010) Cell Signaling by Receptor Tyrosine Kinases. Cell, 141, 1117-1134.
https://doi.org/10.1016/j.cell.2010.06.011 |
| [16] | Siegfried, J.M., Lin, Y., Diergaarde, B., Lin, H.M., Dacic, S., Pen-nathur, A., Weissfeld, J.L., Romkes, M., Nukui, T. and Stabile, L.P. (2015) Expression of PAM50 Genes in Lung Can-cer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome. Neoplasia, 17, 817-825.
https://doi.org/10.1016/j.neo.2015.11.002 |
| [17] | Liles, J.S., Arnoletti, J.P., Tzeng, C.W.D., Howard, J.H., Kossen-kov, A.V., Kulesza, P., Heslin, M.J. and Frolov, A. (2010) ErbB3 Expression Promotes Tumorigenesis in Pancreatic Adenocarcinoma. Cancer Biology & Therapy, 10, 555-563.
https://doi.org/10.4161/cbt.10.6.12532 |
| [18] | Reschke, M., Mihic-Probst, D., Van Horst, E.H., Der Knyazev, P., Wild, P.J., Hutterer, M., Meyer, S., Dummer, R., Moch, H. and Ullrich, A. (2008) HER3 Is a Determinant for Poor Prognosis in Melanoma. Clinical Cancer Research, 14, 5188-5197. https://doi.org/10.1158/1078-0432.CCR-08-0186 |
| [19] | Koumakpayi, I.H., Diallo, J.S., Le Page, C., Lessard, L., Gleave, M., Bégin, L.R., Mes-Masson, A.M. and Saad, F. (2006) Expression and Nuclear Localization of ErbB3 in Prostate Cancer. Clinical Cancer Research, 12, 2730-2737.
https://doi.org/10.1158/1078-0432.CCR-05-2242 |
| [20] | Lipton, A., Goodman, L., Leitzel, K., Cook, J., Sperinde, J., Haddad, M., K？stler, W.J., Huang, W., Weidler, J.M., Ali, S., et al. (2013) HER3, p95HER2, and HER2 Protein Ex-pression Levels Define Multiple Subtypes of HER2-Positive Metastatic Breast Cancer. Breast Cancer Research and Treatment, 141, 43-53.
https://doi.org/10.1007/s10549-013-2665-0 |
| [21] | Khongorzul, P., Ling, C.J., Khan, F.U., Ihsan, A.U. and Zhang, J. (2020) Antibody-Drug Conjugates: A Comprehensive Review. Molecular Cancer Research, 18, 3-19. https://doi.org/10.1158/1541-7786.MCR-19-0582 |
| [22] | Joubert, N., Beck, A., Dumontet, C. and Dene-vault-Sabourin, C. (2020) Antibody-Drug Conjugates: The Last Decade. Pharmaceuticals, 13, Article No. 245. https://doi.org/10.3390/ph13090245 |
| [23] | 邓在春, 虞亦鸣, 胡居根, 等. 人表皮生长因子受体4在13种实体瘤中的表达[J]. 中华实验外科杂志, 2009, 26(7): 946. |
| [24] | 徐新宇, 李刚, 夏雷, 等. 胃癌中HER-3和HER-4的表达及临床意义[J]. 江苏医药, 2013, 39(5) : 533-536. |
| [25] | Zhao, W.X., Liu, Z.F., Li, X.L., et al. (2019) Correlations of serum Homocysteine, VEGF and Gastrin 17 with Gastric Cancer and Precancerous Lesions. European Review for Medical and Pharmacological Sciences, 23, 4192-4198. |
| [26] | Natsume, M., Shimura, T., Iwasaki, H., et al. (2019) Pla-cental Growth Factor Is a Predictive Biomarker for Ramucirumab Treatment in Advanced Gastric Cancer. Cancer Chem-otherapy and Pharmacology, 83, 1037-104.
https://doi.org/10.1007/s00280-019-03817-2 |
| [27] | Khan, U. and Shah, M.A. (2019) Ramucirumab for the Treat-ment of Gastric or Gastro-Esophageal Junction Cancer. Expert Opinion on Biological Therapy, 19, 1135-1141. https://doi.org/10.1080/14712598.2019.1656715 |
| [28] | Murahashi, S., Takahari, D., Wakatsuki, T., et al. (2018) A Retrospective Analysis of Ramucirumab Monotherapy in Previously Treated Japanese Patients with Advanced or Meta-static Gastric Adenocarcinoma. International Journal of Clinical Oncology, 23, 92-97. https://doi.org/10.1007/s10147-017-1192-0 |
| [29] | Fuchs, C.S., Shitara, K., Di Bartolomeo, M., et al. (2019) Ramu-cirumab with Cisplatin and Fluoropyrimidine as First- Line Therapy in Patients with Metastatic Gastric or Junctional Adenocarcinoma (RAINFALL): A Doubleblind, Randomised, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 20, 420-435. |
| [30] | 杨洪娟. 替吉奥联合阿帕替尼治疗晚期胃癌的临床疗效观察[J]. 现代养生, 2022, 22(16): 1335-1338. |
| [31] | 王俊斌, 王栓虎, 张露, 吴骁, 周海荣, 曾会会. 低剂量阿帕替尼联合化疗二线治疗对晚期胃癌患者的疗效[J]. 中国临床研究, 2022, 35(5): 622-626. https://doi.org/10.13429/j.cnki.cjcr.2022.05.006 |
| [32] | 张国政, 张金花, 候慧科. 贝伐珠单抗注射液联合5-氟尿嘧啶、顺铂腹腔灌注热化疗治疗中晚期胃癌的疗效及对血清肿瘤标志物水平的影响[J]. 肿瘤基础与临床, 2018, 31(1): 81-83. |
| [33] | Zhang, J., Gao, B.L., Zhang, W.C., et al. (2018) Monitoring Antiangiogenesis of Bevacizumab in Zebrafish. Drug Des Devel Ther, 12, 2423-2430. https://doi.org/10.2147/DDDT.S166330 |
| [34] | 刘柳. 贝伐珠单抗联合化疗治疗晚期胃癌的疗效观察[J]. 中国实用医药, 2022, 17(5): 134-136. |
| [35] | 王明媚, 马建丽, 王心慧, 卫晋菲, 李莎, 许玉莲. 117例贝伐珠单抗注射液致药品不良反应的特点分析[J]. 中国医院用药评价与分析, 2020, 20(7): 872-875. https://doi.org/10.14009/j.issn.1672-2124.2020.07.026 |
| [36] | Patel, S.P. and Kurzrock, R. (2015) PD-L1 Expres-sion as a Predictive Biomarker in Cancer Immunotherapy. Molecular Cancer Therapeutics, 14, 847-885. https://doi.org/10.1158/1535-7163.MCT-14-0983 |
| [37] | Sharpe, A.H. and Pauken, K.E. (2018) The Diverse Func-tions of the PD1 Inhibitory Pathway. Nature Reviews Immunology, 18, 153-167. https://doi.org/10.1038/nri.2017.108 |
| [38] | Park, H.J., Kusnadi, A., Lee, E.J., et al. (2012) Tumor-Infiltrating Regu-latory T Cells Delineated by Upregulation of PD-1 and Inhibitory Receptors. Cellular Immunology, 278, 76-83. https://doi.org/10.1016/j.cellimm.2012.07.001 |
| [39] | Sugita, G., Fujimori, M. and Ikeda, K. (2005) Immu-no-Histological and -Cytological Examinations on Distribution of Newly Reported Co-Stimulatory Molecules in Germi-nal Center of Human Tonsils. Nihon Jibiinkoka Gakkai Kaiho, 108, 31-37. https://doi.org/10.3950/jibiinkoka.108.31 |
| [40] | Boku, N., Ryu, M.H., Kato, K., et al. (2019) Safety and Efficacy of Nivolumab in Combination with S-1/Capecitabine Plus Oxaliplatin in Patients with Previously Untreated, Unresectable, Advanced, or Recurrent Gastric/Gastroesophageal Junction Cancer: Interim Results of a Randomized, Phase II Trial (ATTRACTION-4). Annals of Oncology, 30, 250-258.
https://doi.org/10.1093/annonc/mdy540 |
| [41] | 包涓, 卿磊, 何新荣, 辛海莉. 纳武利尤单抗致不良反应的文献分析[J]. 中国药物应用与监测, 2021, 18(5): 318-321. |
| [42] | Kwok, G., Yau, T.C., Chiu, J.W., et al. (2016) Pembroli-zumab (Keytruda). Human Vaccines & Immunotherapeutics, 12, 2777-2789. https://doi.org/10.1080/21645515.2016.1199310 |
| [43] | Burtness, B., Harrington, K.J., Greil, R., et al. (2019) Pem-Brolizumab Alone or with Chemotherapy versus Cetuximab with Chemotherapy versus Cetuximab with Chemo-therapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE-048): A Randomised, Open-Label, Phase 3 Study. The Lancet, 394, 1915-1928. |
| [44] | 沈奥林, 胡世莲, 沈国栋. PD-1/PD-L1抗体治疗胃肠道癌症的研究进展[J]. 中国临床保健杂志, 2020, 23(6): 855-859. |
| [45] | Pardoll, D.M. (2012) The Blockade of Im-mune Checkpoints in Cancer Immunotherapy. Nature Reviews Cancer, 12, 252-264. https://doi.org/10.1038/nrc3239 |
| [46] | Ramagopal, U.A., Liu, W.F., Garrett-Thomson, S.C., et al. (2017) Structural Basis for Cancer Immunotherapy by the First-in-Class Checkpoint Inhibitor Ipilimumab. Proceedings of the National Academy of Sciences of the United States of America, 114, E4223-E4232. https://doi.org/10.1073/pnas.1617941114 |
| [47] | Pinto, J.A., Raez, L.E., Oliveres, H., et al. (2019) Current Knowledge of Ipilimumab and Its Use in Treating Non- Small Cell Lung Cancer. Expert Opinion on Biological Therapy, 19, 509-515.
https://doi.org/10.1080/14712598.2019.1610380 |
| [48] | None (2010) Tremelimumab. Drugs in R&D, 10, 123-132. https://doi.org/10.2165/11584530-000000000-00000 |
| [49] | Xu, M., Chen, X., Lin, K., Zeng, K., Liu, X., Xu, X., Pan, B., Xu, T., Sun, L., He, B., Pan, Y., Sun, H. and Wang, S. (2019) LncRNA SNHG6 Regulates EZH2 Expression by Sponging miR-26a/b and miR-214 in Colorectal Cancer. Journal of Hematology & Oncology, 12, 3. https://doi.org/10.1186/s13045-018-0690-5 |
| [50] | Wang, X., Lai, Q., He, J., Li, Q., Ding, J., Lan, Z., Gu, C., Yan, Q., Fang, Y., Zhao, X. and Liu, S. (2019) LncRNA SNHG6 Promotes Proliferation, Invasion and Migration in Colorec-tal Cancer Cells by Activating TGF-Beta/Smad Signaling Pathway via Targeting UPF1 and Inducing EMT via Regulation of ZEB1. International Journal of Medical Sciences, 16, 51-59. https://doi.org/10.7150/ijms.27359 |
| [51] | Lan, Z., Yao, X., Sun, K., Li, A., Liu, S. and Wang, X. (2020) The Interaction between lncRNA SNHG6 and hnRNPA1 Con-tributes to the Growth of Colorectal Cancer by Enhancing Aerobic Glycolysis through the Regulation of Alternative Splicing of PKM. Frontiers in Oncology, 10, Article No. 363. https://doi.org/10.3389/fonc.2020.00363 |
| [52] | Steinman, R.M. (2012) Decisions about Dendritic Cells: Past, Pre-sent, and Future. Annual Review of Immunology, 30, 1-22. https://doi.org/10.1146/annurev-immunol-100311-102839 |
| [53] | Aleixo, A.A., Michelin, M.A. and Murta, E.F. (2014) Dendritic Cell Vaccine and Cancer Treatment: New Patents. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 8, 26-29.
https://doi.org/10.2174/1872214807666140107152008 |
| [54] | 仁爱军. 术后化疗联合DC-CIK生物治疗胃癌的疗效观察[J]. 河北医学, 2014, 20(6): 972-975. |
| [55] | 叶圣权, 宋宇, 孙丽云, 王欢. 晚期胃癌化疗联合过继免疫细胞治疗对生命质量的影响及疗效[J]. 武警医学, 2017, 28(5): 443-446. |
| [56] | Tada, Y., Togashi, Y., Kotani, D., et al. (2018) Targeting VEGFR2 with Ramucirumab Strongly Impacts Effector/ Activated Regulatory T Cells and CD8+ T Cells in the Tumor Microenvironment. Journal for ImmunoTherapy of Cancer, 6, 106. https://doi.org/10.1186/s40425-018-0403-1 |
| [57] | Feng, Y., Dai, Y., Gong, Z.H., et al. (2018) Association between Angiogenesisand Cytotoxic Signatures in the Tumor Microenvironment of Gastric Cancer. OncoTargets and Therapy, 11, 2725-2733. https://doi.org/10.2147/OTT.S162729 |
